Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 742-749

  Holyoake, Andrew ^a   O'Sullivan, Paul ^a   Pollock, Rob ^a   Best, Terry ^a   Watanabe, Jun ^b   Kajita, Yoichiro ^b   Matsui, Yoshiyuki ^b   Ito, Masaaki ^b   Nishiyama, Hiroyuki ^b   Kerr, Natalie ^a   Tatley, Fernanda Da Silva ^a   Cambridge, Lisa ^a   Toro, Tumi ^a   Ogawa, Osamu ^b   Guilford, Parry ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

AGED; ARTICLE; BLADDER CARCINOGENESIS; BLADDER MUSCLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CDC2 GENE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GENE; GENE EXPRESSION PROFILING; HEMATURIA; HOXA13 GENE; HUMAN; HUMAN TISSUE; IGFBP5 GENE; JAPAN; MAJOR CLINICAL STUDY; MDK GENE; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINARY TRACT INFECTION;

CARCINOMA, TRANSITIONAL CELL; HUMANS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; ROC CURVE; URINARY BLADDER NEOPLASMS;

EID: 38949111436     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1672     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol 2006;24:5519-27.
3. Dryson E, Walls C, McLean D, Pearce N. Occupational bladder cancer in New Zealand: a 1-year review of cases notified to the New Zealand Cancer Registry. Intern Med J 2005;35:343-7.
4. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
5. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-6.
6. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89.
7. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029-36.
8. Thykjaer T, Workman C, Kruhoffer M, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 2001;61:2492-9.
9. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002;62:6973-80.
10. Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
11. Ito M, Nishiyama H, Kawanishi H, et al. P21-activated kinase1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. J Urol 2007;178:1073-9.
12. Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ, Southgate J. Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest 1997;76:843-57.
13. Menke TB, Warnecke JM. Improved conditions for isolation and quantification of RNA in urine specimens. Ann N Y Acad Sci 2004;1022:185-9.
14. Natvig J, Perlmann P, Wigzell H, editors. Lymphocytes. Isolation, fractionation and characterization. Oslo: Universitetsforlaget, 1976. p.184.
15. Fawcett T. ROC graphs: notes and practical considerations for researchers. Palo Alto (CA): Hewlett-Packard Laboratories; 2004.
16. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005;21:3940-1.
17. Scott V, Morgan EA, Stadler HS. Genitourinary functions of Hoxa13 and Hoxd13. J Biochem (Tokyo) 2005;137:671-6.
18. Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 2006;395:1-19.
19. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004;204:127-43.
20. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169:1975-82.
21. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-6.
22. Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006;176:44-7.
23. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-4.
24. Sanchez-Carbayo M, Urrutia M, Silva JM, Romani R, De Buitrago JM, Navajo JA. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001;165:1462-7.
25. Smellie WS, Forth JO, McNulty CA, et al. Best practice in primary care pathology: review 2. J Clin Pathol 2006;59:113-20.
26. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736-48.
27. Wang Y. Gene expression-driven diagnostics and pharmacogenomics in cancer. Curr Opin Mol Ther 2005;7:246-50.
28. Dyrskjot L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007;13:3545-51.
29. Maruniak NA, Takezawa K, Murphy WM. Accurate pathological staging of urothelial neoplasms requires better cystoscopic sampling. J Urol 2002;167:2404-7.
30. Liedberg F, Anderson H, Mansson A, Mansson W. Diagnostic delay and prognosis in invasive bladder cancer. Scand J Urol Nephrol 2003;37:396-400.
31. Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S. Delay and survival in bladder cancer. BJU Int 2002;89:868-78.
32. Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169:110-5; discussion 5.
33. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA, Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003;170:1085-7.